| Prev Close | 0.35 |
| Day Low/High | 0.33 / 0.36 |
| 52 Wk Low/High | 0.26 / 1.27 |
CytRx Announces Positive Results From Animal Trial With Combination Aldoxorubicin And Doxorubicin Therapy
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that an in vivo trial investigating aldoxorubicin, its tumor-targeting conjugate of...
CytRx Promotes Dr. Daniel Levitt To Executive Vice President
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, has named Daniel Levitt, M.
CytRx To Present At The Biotech Showcase 2013 Conference
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A.
CytRx’s Aldoxorubicin Clinical Data Presented At Connective Tissue Oncology Society (CTOS) 7th Annual Meeting In Prague, Czech Republic
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced the presentation today of favorable results from a Phase 1b/2 clinical trial with its ...
CytRx Reports Third Quarter 2012 Financial Results
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2012.
5 Stocks With Big Insider Buying
Insiders at these companies have been scooping up shares of their own stock lately.
CytRx Announces Closing Of Public Offering Of Common Stock
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the closing of its previously announced underwritten public offering of 9,200,000 shares...
CytRx Announces Exercise Of Underwriters’ Over-Allotment Option
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the sale of an additional 1,200,000 shares of common stock pursuant to the exercise in...
Insiders Trading DVA CYTR JBHT HNSN
The top 10 open-market insider purchases and sales filed at the SEC Thursday.
CytRx Announces Pricing Of Public Offering Of 8 Million Shares Of Common Stock
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the pricing of its previously announced underwritten public offering.
CytRx Announces Proposed Public Offering Of Common Stock
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today its intention, subject to market and other conditions, to commence a public offering of...
CytRx Advancing Aldoxorubicin (INNO-206) Development With Pharmacokinetic Study In Patients With Metastatic Solid Tumors
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, has initiated an open-label, single-center Phase 1b clinical trial to evaluate the pharmacokinetics of its tumor-targeting ...
CytRx’s Aldoxorubicin Clinical Data Presented At The ESMO 2012 Congress
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announced that favorable data from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin ...
CytRx To Present At The 2012 Aegis Healthcare Conference
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A.
CytRx’s Aldoxorubicin Clinical Data Selected For Presentation At Preeminent Sarcoma Conference
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that favorable results from a Phase 1b/2 clinical trial with aldoxorubicin (formerly INNO-206) in patients with ...
CytRx To Present At The Rodman & Renshaw 14th Annual Global Investment Conference
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A.
CytRx Reports Second Quarter 2012 Financial Results
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2012, and provided a business update.
CytRx’s Aldoxorubicin (INNO-206) Clinical Data To Be Featured At The ESMO 2012 Congress
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announced that favorable results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate ...
CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin (INNO-206) And Doxorubicin In Patients With Advanced Solid Tumors
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary ...
CytRx’s Tamibarotene Continues To Protect Touring Professional Musician And Former NBA Player Ray Johnston From Leukemia
For more than two years, former Dallas Maverick basketball player Ray Johnston has been cancer-free.
CytRx Announces Allowance Of U.S. Patent Application For Tamibarotene Capsule
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that the U.
5 Stocks With Big Insider Buying
Insiders at these companies have been scooping up shares of their own stock lately.
CytRx Announces Issuance Of European Patent Covering INNO-206 Linker Technology
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company’s tumor-targeting linker...
Major Milestone Achieved In CytRx’s Phase 2b Global Clinical Trial With Tamibarotene As A First-Line Treatment For Non-Small-Cell Lung Cancer
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical ...
CytRx Set To Join The Russell Microcap Index
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that it is expected to join the Russell Microcap® Index when Russell Investments reconstitutes its family of...
CytRx To Hold Conference Call Today At 10:00 A.m. Eastern Time To Discuss Favorable Results From INNO-206 Clinical Trial In Soft Tissue Sarcoma
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, will hold a conference call to discuss favorable clinical results from the Phase 1b/2 clinical trial with INNO-206 in patients ...
CytRx Announces Favorable Results From Phase 1b/2 Clinical Trial With INNO-206
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announces that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate ...
CytRx Regains NASDAQ Compliance
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it received written notification on May 31, 2012 from the NASDAQ Listing Qualifications Department that it ...
CytRx Announces The Publication Of INNO-206 Findings In Multiple Myeloma In Clinical Cancer Research
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple ...
CytRx Initiates Phase 2 Clinical Trial With INNO-206 In Pancreatic Cancer
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients...
